Phillips-Medisize Expands - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Phillips-Medisize Expands



Phillips-Medisize, an outsource provider of design and manufacturing services for medical devices and drug delivery markets, reports the start of production and completion of the 60,000-ft2expansion to its Kontiolahti, Finland site. Production has already begun and will continue to ramp up several new programs before the first of the year. The site focuses on the industrialization and production of inhalers, insulin pens, transfer devices, and syringes.

The expansion includes 12,900 ft2 of Class 8 clean-room manufacturing and assembly and has space for the additional expansion for molding machines and assembly. New high-speed automation lines enable the ramp up of multi-component, complex drug-delivery devices from prototype to high-speed automated 24/7 mass production under competitive cost-structure. Total Kontiolahti numbers now include, multiple high-speed, fully automated assembly lines, fully automated printing lines, and several semi-automated lines.

Source: Phillips-Medisize

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here